Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of RO0503821 in anemic NSCLC patients receiving first-line chemotherapy
2005-005405-37Phase 2Terminated
- Sponsor
- Roche
- Start
- Jan 2006
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methoxy polyethylene glycol-epoetin beta in non-small cell lung cancer (NSCLC) and anemia (CIA) (2 arms), sponsored by Roche. Primary endpoint: Average hemoglobin change from baseline during weeks 5–13. Started Jan 2006; status: terminated.
02
Drugs
methoxy polyethylene glycol-epoetin beta
03
Conditions
non-small cell lung cancer (NSCLC)anemia (CIA)
Beyond the preview
Go deeper on 2005-005405-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005405-37.